Twist Bioscience Corporation (TWST)
NASDAQ: TWST · Real-Time Price · USD
32.21
-1.36 (-4.05%)
At close: Oct 29, 2025, 4:00 PM EDT
32.00
-0.21 (-0.65%)
After-hours: Oct 29, 2025, 6:00 PM EDT
Twist Bioscience Revenue
Twist Bioscience had revenue of $96.06M in the quarter ending June 30, 2025, with 17.91% growth. This brings the company's revenue in the last twelve months to $362.27M, up 22.72% year-over-year. In the fiscal year ending September 30, 2024, Twist Bioscience had annual revenue of $312.97M with 27.69% growth.
Revenue (ttm)
$362.27M
Revenue Growth
+22.72%
P/S Ratio
5.50
Revenue / Employee
$392,495
Employees
923
Market Cap
1.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 312.97M | 67.87M | 27.69% |
| Sep 30, 2023 | 245.11M | 41.54M | 20.41% |
| Sep 30, 2022 | 203.57M | 71.23M | 53.83% |
| Sep 30, 2021 | 132.33M | 42.23M | 46.87% |
| Sep 30, 2020 | 90.10M | 35.72M | 65.67% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TWST News
- 5 days ago - Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 6 days ago - Twist Bioscience to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results on Friday, November 14, 2025 - Business Wire
- 23 days ago - Twist Bioscience and Element Biosciences Advance Collaboration with Launch of New Trinity Freestyle™ Sequencing Workflow for the AVITI™ System - Business Wire
- 27 days ago - Twist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein Design - Business Wire
- 2 months ago - Twist Bioscience to Present at Baird 2025 Global Healthcare Conference - Business Wire
- 2 months ago - Twist Bioscience Collaborates with Synthetic Design Lab - Business Wire
- 2 months ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha
- 2 months ago - Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution - Business Wire